Aktuellt
SENASTE
Redeye has a positive view on the news from this morning, announcing that Saniona's collaboration with Boehringer Ingelheim has progressed to the lead optimization stage. This milestone has triggered a payment of approximately SEK5.7m to Saniona. The company remains eligible for up to EUR76.5m in additional milestones, as well as royalties, in the partnership focused on cognitive impairment in schizophrenia. We view this as an additional validation of Saniona's ion channel platform, with the milestone payment also contributing somewhat to the company's cash position.
LÄS MER
